Skip to main content
Premium Trial:

Request an Annual Quote

Parse Biosciences Partners With Decode Science for Australia, New Zealand Distribution

NEW YORK – Parse Biosciences announced on Tuesday that it has partnered with Decode Science to distribute its single-cell RNA-seq solutions in Australia and New Zealand.

Under the terms of the deal, Decode will provide customer service, technical support, sales and marketing, distribution, and related logistical efforts for the Parse product line — specifically its whole transcriptome, cell fixation, and nuclei fixation kits.

Decode is a distributor of genomic and multiomic products with established relationships at key accounts in the Oceania region, Parse said in a statement.

"We see these markets contributing substantially to our success and found the perfect partner in Decode," said Alex Rosenberg, CEO and cofounder of Seattle-based Parse Biosciences.

Parse Biosciences introduced split-pool combinatorial barcoding to the market earlier this year. The technology is an intrinsically scalable single-cell RNA-seq that does not require a separate hardware purchase, the firm said.

The Parse Bioscience Whole Transcriptome Kit is a single-cell assay that enables the profiling of up to 48 samples and 100,000 cells or nuclei. The Cell Fixation Kit and Nuclei Fixation Kit enable researchers to fix and store suspensions for up to six months.

Parse Biosciences noted that it will also present new capabilities of its platform at this year's American Society of Human Genetics meeting.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more